Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations

Abstract

These results suggest that therapies, such as hematopoietic stem cell transplantation, which are potentially curative although associated with a risk of treatment-related mortality, should not be postponed even in those CAMT patients whose c-MPL mutations might predict residual activity of the TPO receptor.